Theravance Biopharma (NASDAQ:TBPH) Reaches New 52-Week High - Should You Buy?

Key Points

• Theravance Biopharma's share price reached a new 52-week high of $14.55 during trading, with a last known price of $14.21.
• Multiple analysts have upgraded the stock's rating to "strong-buy", with the average price target among analysts set at $23.00.
• Insiders own 6.90% of the stock, and recent transactions show significant activity, including a sale of 10,000 shares by a senior vice president.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as $14.55 and last traded at $14.21, with a volume of 172 shares changing hands. The stock had previously closed at $14.40.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TBPH shares. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. B. Riley started coverage on shares of Theravance Biopharma in a research note on Friday, September 12th. They set a "buy" rating and a $28.00 target price for the company. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research note on Tuesday, June 17th. Zacks Research downgraded shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Monday. Finally, BTIG Research raised their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, June 27th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Theravance Biopharma presently has an average rating of "Buy" and an average target price of $23.00.

Theravance Biopharma Price Performance

The company has a market cap of $699.00 million, a P/E ratio of 57.83 and a beta of 0.05. The company's 50-day moving average is $12.62 and its two-hundred day moving average is $10.73.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the sale, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. This trade represents a 2.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 3,281 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock worth $55,000 after purchasing an additional 781 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Theravance Biopharma in the first quarter worth approximately $101,000. R Squared Ltd boosted its holdings in Theravance Biopharma by 636.6% in the first quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock worth $112,000 after purchasing an additional 10,822 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Theravance Biopharma in the fourth quarter worth approximately $119,000. Hedge funds and other institutional investors own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.